Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Biohaven (NYSE: BHVN) announced that Vlad Coric, M.D., Chairman and CEO, will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biohaven (NYSE: BHVN) announced that Vlad Coric, M.D., Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PST (11:15 a.m. EST). The presentation is scheduled for The Westin St. Francis Hotel in San Francisco, California.
Details
News Market Reaction – BHVN
On Jan 7, the day this news came out, BHVN closed 22.04% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Current price
- $9.62
- BHVN pre-news trading level
- Daily price change
- -3.12%
- Change over prior 24 hours
- Volume today
- 3,145,669 shares
- Session volume before news
- 20-day avg volume
- 3,185,372 shares
- Average trading volume benchmark
- 52-week high
- $44.2803
- Trailing 12-month high price
- 52-week low
- $7.48
- Trailing 12-month low price
- Market capitalization
- $1,317,596,696
- Equity value before conference news
- Conference time
- 8:15 a.m. PST (11:15 a.m. EST)
- Scheduled J.P. Morgan Healthcare Conference presentation on Jan 12, 2026
Historical Context
-
Phase 2 BHV-7000 MDD trial failed primary endpoint but stock rose modestly.
-
Phase 1 BHV-1510 combo showed high ORR and favorable safety profile.
-
Closed upsized equity offering with ~$200M gross proceeds; shares gained.
-
Priced $175M equity offering at $7.50; stock fell following the announcement.
-
Proposed $150M share offering yet shares rose strongly after the news.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nyse financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's key clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE™ and TRAP™ extracellular protein degraders for immunological diseases; and myostatin-activin pathway targeting agents for neuromuscular and metabolic diseases, including SMA and obesity. For more information, visit www.biohaven.com.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potential first-in-class", "potentially", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDE and TRAP are trademarks of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
+1 (615) 414-8668
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-january-12-2026-302654353.html
SOURCE Biohaven Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.